Inhaled steroids in COPD: When should they be used?

The Lancet Respiratory Medicine

Volumn 2, Issue 11, 2014, Pages 869-871

  Agusti, Alvar ^a   Fabbri, Leonardo M ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; ANTIINFLAMMATORY AGENT;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; MONOTHERAPY; MORTALITY; NOTE; PNEUMONIA; CONTRAINDICATIONS; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84918801105     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70227-9     Document Type: Note

References (14)

1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
2. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31:143-178.
3. Zervas E, Samitas K, Gaga M, Beghe B, Fabbri LM Inhaled corticosteroids in COPD: pros and cons. Curr Drug Targets 2013, 14:192-224.
4. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008, 178:332-338.
5. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. New Engl J Med 2014, 371:1285-1294.
6. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
7. Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting beta-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014, 312:1114-1121.
8. Finney L, Berry M, Singanayagam A, Elkin SL, Johnston SL, Mallia P Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med 2014, 2:919-932.
9. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26.
10. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013, 1:51-60.
11. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750.
12. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146:545-555.
13. Agusti A, Hurd S, Jones P, et al. Frequently asked questions (FAQs) about the GOLD 2011 assessment proposal of COPD. Eur Respir J 2013, 42:1391-1401.
14. Calverley PM Treating COPD in the real world. JAMA 2014, 312:1101-1102.